<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898114</url>
  </required_header>
  <id_info>
    <org_study_id>Neb-Mag-2</org_study_id>
    <nct_id>NCT04898114</nct_id>
  </id_info>
  <brief_title>Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn</brief_title>
  <official_title>Effectiveness of Nebulized Magnesium Sulfate Combined With Sildenafil Citrate in Persistent Pulmonary Hypertension of Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate&#xD;
      combined with sildenafil citrate, compared with sildenafil citrate alone, in treating&#xD;
      neonates with severe persistent pulmonary hypertension on mechanical ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent pulmonary hypertension of newborn (PPHN) is a serious condition that results from&#xD;
      failure of the normal postnatal circulatory transition and is associated with significant&#xD;
      mortality and morbidity. Advanced medical treatment, such as inhaled nitric oxide (iNO),&#xD;
      high-frequency ventilation (HFV), and extracorporeal membrane oxygenation (ECMO) are commonly&#xD;
      not available in developing countries. Intravenous magnesium sulfate has been shown to&#xD;
      alleviate pulmonary hypertension but is associated with systemic hypotension and is less&#xD;
      effective compared with iNO and sildenafil. Nebulized magnesium sulfate has been reported to&#xD;
      be more effective and safer compared with intravenous magnesium sulfate in treating neonates&#xD;
      with PPHN on mechanical ventilation. Combined nebulized magnesium and sildenafil has been&#xD;
      studied in a small trial on spontaneously breathing neonates with PPHN but not on those&#xD;
      connected to mechanical ventilation.&#xD;
&#xD;
      The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate&#xD;
      combined with sildenafil citrate, compared with sildenafil citrate alone, in treating&#xD;
      neonates with severe PPHN on mechanical ventilation. We hypothesize that neonates with severe&#xD;
      PPHN connected to mechanical ventilation could benefit from taking continuous nebulization of&#xD;
      magnesium sulfate combined besides sildenafil.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups of neonates with PPHN on mechanical ventilation: (1) NebMag group: receive nebulized magnesium sulfate and oral sildenafil citrate; (2) Control group: receive nebulized placebo (isotonic saline) and oral sildenafil citrate.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Each neonate will be assigned a unique identification number. Pharmacy will fill the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, nurses, echocardiographers, and data collectors will be unaware of group assignment and drug/placebo therapy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Oxygenation index (OI)</measure>
    <time_frame>From baseline to 2, 6, 12, and 24 hours following study drug administration</time_frame>
    <description>OI will be calculated using the following formula: OI = [(FiO2 × MAP) / PaO2] (FiO2, fraction of inspired oxygen expressed in %; MAP, mean airway pressure in cmH2O/mmHg; and PaO2, partial pressure of arterial oxygen in mmHg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean arterial blood pressure (MABP)</measure>
    <time_frame>From baseline to 2, 6, 12, and 24 hours following study drug administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vasoactive Inotropic Score (VIS)</measure>
    <time_frame>From baseline to 2, 6, 12, and 24 hours following study drug administration.</time_frame>
    <description>The VIS will be calculated using the following formula: VIS = dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 × epinephrine dose (µg/kg/min) + 100 × norepinephrine dose (µg/kg/min) + 10 × milrinone dose (µg/kg/min) + 10,000 × vasopressin dose (U/kg/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary artery systolic pressure (PASP)</measure>
    <time_frame>From baseline to 24 hours after study drug administration</time_frame>
    <description>PASP will be estimated by echocardiography using the modified Bernoulli equation: PASP = (TRJV2 × 4) + RAP (TRJV, tricuspid regurgitation jet velocity; RAP, right atrial pressure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum magnesium level</measure>
    <time_frame>From baseline to 24 hours after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Persistent Pulmonary Hypertension of Newborn</condition>
  <arm_group>
    <arm_group_label>NebMag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized magnesium sulfate and oral sildenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nebulized placebo (isotonic saline) and oral sildenafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes</description>
    <arm_group_label>NebMag</arm_group_label>
    <other_name>MgSO4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate</intervention_name>
    <description>Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>NebMag</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>Nebulized isotonic saline (4 ml) every 15 minutes</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>0.9% NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age ≥ 36 weeks&#xD;
&#xD;
          -  Birth weight between 2.5 and 4 kg.&#xD;
&#xD;
          -  Post-natal age between 6 and 72 hours.&#xD;
&#xD;
          -  PPHN confirmed by echocardiography&#xD;
&#xD;
          -  Oxygenation index (OI) &gt; 30 on two occasions at least 15 minutes apart&#xD;
&#xD;
          -  Connected to Mechanical Ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to obtain informed consent&#xD;
&#xD;
          -  Newborns to mothers who received magnesium sulfate within 48 hours before labor.&#xD;
&#xD;
          -  Congenital heart diseases, other than patent ductus arteriosus and foramen ovale.&#xD;
&#xD;
          -  Major congenital anomalies (including congenital diaphragmatic hernia and lung&#xD;
             hypoplasia).&#xD;
&#xD;
          -  Prior need for cardiopulmonary resuscitation.&#xD;
&#xD;
          -  Mean arterial blood pressure (MABP) &lt; 35 mmHg despite therapy with volume infusions&#xD;
             and vasoactive inotropes.&#xD;
&#xD;
          -  Impaired kidney function.&#xD;
&#xD;
          -  Prior administration of pulmonary vasodilators.&#xD;
&#xD;
          -  Gastrointestinal intolerance or bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elsayed Abdelkreem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elsayed Abdelkreem, MD, PhD</last_name>
    <phone>00201114232126</phone>
    <email>d.elsayedmohammed@med.sohag.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostafa Abo-Sidera, MD, PhD</last_name>
      <phone>1002028668</phone>
      <phone_ext>0020</phone_ext>
      <email>aabosdera@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Abdelkreem E, Mahmoud SM, Aboelez MO, Abd El Aal M. Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of Newborn: A Pilot Randomized Controlled Trial. Indian J Pediatr. 2021 Aug;88(8):771-777. doi: 10.1007/s12098-020-03643-y. Epub 2021 Jan 8.</citation>
    <PMID>33415555</PMID>
  </reference>
  <reference>
    <citation>Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2021 Mar;56(3):661-669. doi: 10.1002/ppul.25073. Review.</citation>
    <PMID>32930508</PMID>
  </reference>
  <reference>
    <citation>El-Khuffash A, McNamara PJ, Breatnach C, Bussmann N, Smith A, Feeney O, Tully E, Griffin J, de Boode WP, Cleary B, Franklin O, Dempsey E. The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1): study protocol and review of literature. Matern Health Neonatol Perinatol. 2018 Dec 3;4:24. doi: 10.1186/s40748-018-0093-1. eCollection 2018. Review.</citation>
    <PMID>30524749</PMID>
  </reference>
  <reference>
    <citation>Lai MY, Chu SM, Lakshminrusimha S, Lin HC. Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Pediatr Neonatol. 2018 Feb;59(1):15-23. doi: 10.1016/j.pedneo.2016.09.011. Epub 2017 Aug 10. Review.</citation>
    <PMID>28923474</PMID>
  </reference>
  <reference>
    <citation>Nakwan N. The Practical Challenges of Diagnosis and Treatment Options in Persistent Pulmonary Hypertension of the Newborn: A Developing Country's Perspective. Am J Perinatol. 2018 Dec;35(14):1366-1375. doi: 10.1055/s-0038-1660462. Epub 2018 Jun 19. Review.</citation>
    <PMID>29920641</PMID>
  </reference>
  <reference>
    <citation>He Z, Zhu S, Zhou K, Jin Y, He L, Xu W, Lao C, Liu G, Han S. Sildenafil for pulmonary hypertension in neonates: An updated systematic review and meta-analysis. Pediatr Pulmonol. 2021 Aug;56(8):2399-2412. doi: 10.1002/ppul.25444. Epub 2021 May 13. Review.</citation>
    <PMID>33983650</PMID>
  </reference>
  <reference>
    <citation>Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005588. Review.</citation>
    <PMID>17636807</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Elsayed Abdelkreem</investigator_full_name>
    <investigator_title>Lecturer of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>neonate</keyword>
  <keyword>persistent fetal circulation</keyword>
  <keyword>persistent pulmonary hypertension of the newborn</keyword>
  <keyword>PPHN</keyword>
  <keyword>Magnesium Sulfate</keyword>
  <keyword>Nebulizer</keyword>
  <keyword>hypoxia</keyword>
  <keyword>mechanical ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Unidentified individual participant data will be available from the principal investigator upon reasonable request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Three years after publication of the study results</ipd_time_frame>
    <ipd_access_criteria>Unidentified individual participant data can be requested from the principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

